For Healthcare Professionals

A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B


About the study

This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved liver function and without significant fibrosis/cirrhosis. The platform design allows comparison of multiple NME combination therapies against a common control, and introduction of additional treatment arms at later study time points. Each arm will consist of a screening phase (up to 8 weeks), treatment phase (up to 48 weeks) and post-treatment follow-up phase (48 weeks). The safety and efficacy will be monitored throughout the study.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


  1. Body mass index between 18 and 32 kg/m2 inclusive.
  2. Participants with Chronic Hepatitis B (CHB) infection (HBsAg positive for >=6 months) who are on established NUC (entecavir or tenofovir alafenamide/disoproxil fumarate) monotherapy for >=12 months, having received the same NUC therapy for >=3 months prior to screening.
  3. HBV DNA below the lower LLOQ or < 20 IU/mL for > 6 months prior to screening and confirmed at screening.
  4. Alanine transaminase (ALT) <=1.5 x upper limit of normal (ULN) for > 6 months prior to screening and confirmed at screening.
  5. Female Participants: Eligible to participate if she is not pregnant, not breastfeeding and agrees to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods.
  6. Male Participants: During the treatment period and for at least 6 months after the final dose of study treatment, agrees to remain abstinent (refrain from heterosexual intercourse), use contraceptive measures and refrain from donating sperm.


  1. Pregnant or lactating women.
  2. Co-infection with other pathogens such as Hepatitis A, C, D and E or Human Immunodeficiency Virus (HIV).
  3. History of cirrhosis or current evidence of significant liver fibrosis or cirrhosis or decompensated liver disease.
  4. History of or suspicion of Hepatocellular Carcinoma (HCC).
  5. Thyroid disease poorly controlled on prescribed medications or clinically relevant abnormal thyroid function tests.
  6. Clinically significant disease other than CHB that, in the opinion of the Investigator, makes the participant unsuitable for the study.
  7. Pre-existing cardiac disease that in the opinion of the investigator would increase the risk for the participant to take part in the study.
  8. History of alcohol abuse and/or drug abuse within one year of randomization.
  9. History of having received (in the last 6 months) or currently receiving any systemic antineoplastic (including radiation) or immunosuppressive (including biologic immunosuppressors) or immune modulating treatment.
  10. Currently taking, or have received within 3 months of Day 1, systemic corticosteroids.
  11. Electrocardiogram (ECG) with clinically significant abnormalities.
  12. Previous treatment with an investigational agent for Hepatitis B (HBV) within 6 months prior to screening.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 888-662-6728 (U.S and Canada)Email iconEmail Study Center

Study’s details


Hepatitis B, Chronic

Age (in years)

18 - 65


Phase 2

Participants needed


Est. Completion Date

Nov 2024

Treatment type



Hoffmann-La Roche identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.